U.S. stocks steady; Cook’s dismissal, Nvidia earnings in spotlight
Investing.com -- United Therapeutics Corporation (NASDAQ:UTHR) on Wednesday reported second quarter earnings that fell short of analyst expectations, despite achieving record revenue for the period.
The company posted adjusted earnings per share of $6.41, missing the analyst estimate of $7.35 by $0.94, while revenue came in at $798.6 million versus the consensus estimate of $804.98 million.
The biopharmaceutical company’s quarterly revenue grew 12% YoY from $714.9 million in the same quarter last year, marking the 12th consecutive quarter of double-digit revenue growth.
Following the earnings release, United Therapeutics shares were essentially flat, edging up just 0.01%.
Tyvaso DPI was a standout performer with record revenue of $315 million, representing 22% growth over the previous quarter.
The company also reported double-digit YoY revenue growth for Nebulized Tyvaso, Orenitram, and Unituxin, with Orenitram achieving record quarterly revenue.
"Our second quarter yet again produced record-setting results driven by the strength of our foundational commercial business," said Martine Rothblatt, Chairperson and CEO of United Therapeutics.
"We continue to believe there is no other biotech company like ours that provides this combination of sales growth and operating cash flow with near- to medium-term catalysts positioned for sustained long-term growth."
The company announced that its Board of Directors has authorized a share repurchase program of up to $1 billion, expiring March 31, 2026, reflecting confidence in its financial position and future growth prospects.
United Therapeutics also provided updates on its clinical pipeline, noting that its Phase 3 TETON 2 study of Nebulized Tyvaso in idiopathic pulmonary fibrosis is complete, with data expected in September 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.